Area of research
Hepatology · Surgery
Research interest
Research focused on Sorafenib and Hepatocellular carcinoma, with related work in Selective internal radiation therapy, Oncology, Panitumumab. Notable publications include 'Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma', 'FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)', and 'Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial'.
Bleomycin-Electrosclerotherapy in the treatment of superficial slow-flow vascular malformations of head and neck
Additional file 2 of Detection rate and mutational landscape in extracranial arteriovenous malformations: a cohort study
Additional file 3 of Detection rate and mutational landscape in extracranial arteriovenous malformations: a cohort study
Additional file 3 of Detection rate and mutational landscape in extracranial arteriovenous malformations: a cohort study
Additional file 2 of Detection rate and mutational landscape in extracranial arteriovenous malformations: a cohort study
Additional file 1 of Detection rate and mutational landscape in extracranial arteriovenous malformations: a cohort study
Additional file 1 of Detection rate and mutational landscape in extracranial arteriovenous malformations: a cohort study
Impact of Helicobacter pylori on Immune Checkpoint Inhibition in Hepatocellular Carcinoma: A Multicenter Study
Common Practice of Percutaneous Drainage in Necrotising Pancreatitis—A Multicentre Retrospective Study (DRACULA)
Nuclear magnetic resonance-based lipid metabolite profiles for differentiation of patients with liver cirrhosis with and without hepatocellular carcinoma
Prognostic role of radiomics‐based body composition analysis for the 1‐year survival for hepatocellular carcinoma patients
Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board
Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib
Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma
Impact of Pharmaceutical Prophylaxis on Radiation-Induced Liver Disease Following Radioembolization
Image-Guided Local Treatment for Unresectable Intrahepatic Cholangiocarcinoma—Role of Interventional Radiology
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
FOLFOXIRI Plus Panitumumab As First-Line Treatment of <i>RAS</i> Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)
Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial
Secondary technical resectability of colorectal cancer liver metastases after chemotherapy with or without selective internal radiotherapy in the randomized SIRFLOX trial
REsect: Blinded assessment of amenability to potentially curative treatment of previously unresectable colorectal cancer liver metastases (CRC LM) after chemotherapy ± RadioEmbolization (SIRT) in the randomized SIRFLOX trial.